Align Technology, Inc. (NASDAQ:ALGN) Shares Bought by FourThought Financial Partners LLC

FourThought Financial Partners LLC boosted its position in shares of Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 34.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,741 shares of the medical equipment provider's stock after purchasing an additional 3,247 shares during the quarter. FourThought Financial Partners LLC's holdings in Align Technology were worth $3,491,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Commonwealth Equity Services LLC lifted its position in shares of Align Technology by 9.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 5,046 shares of the medical equipment provider's stock worth $1,541,000 after purchasing an additional 435 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in Align Technology by 26.0% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 21,040 shares of the medical equipment provider's stock worth $6,424,000 after buying an additional 4,346 shares during the period. Stratos Wealth Partners LTD. lifted its holdings in Align Technology by 139.7% during the third quarter. Stratos Wealth Partners LTD. now owns 1,704 shares of the medical equipment provider's stock worth $520,000 after buying an additional 993 shares during the period. Stratos Wealth Advisors LLC boosted its position in Align Technology by 51.9% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 1,124 shares of the medical equipment provider's stock valued at $343,000 after acquiring an additional 384 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Align Technology by 2.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,228,875 shares of the medical equipment provider's stock valued at $375,200,000 after acquiring an additional 29,497 shares during the period. 88.43% of the stock is owned by institutional investors.

Insider Buying and Selling at Align Technology

In other news, Director Joseph Lacob sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $313.01, for a total value of $3,130,100.00. Following the completion of the transaction, the director now directly owns 146,994 shares in the company, valued at $46,010,591.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Emory Wright sold 2,524 shares of the business's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $287.45, for a total transaction of $725,523.80. Following the completion of the transaction, the executive vice president now directly owns 709 shares in the company, valued at $203,802.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph Lacob sold 10,000 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $313.01, for a total value of $3,130,100.00. Following the sale, the director now directly owns 146,994 shares in the company, valued at $46,010,591.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,524 shares of company stock worth $8,403,924. 0.62% of the stock is currently owned by insiders.

Align Technology Trading Up 0.5 %

Shares of NASDAQ ALGN traded up $1.33 during midday trading on Friday, reaching $287.87. The company had a trading volume of 353,639 shares, compared to its average volume of 699,892. Align Technology, Inc. has a 1 year low of $176.34 and a 1 year high of $413.20. The business's 50-day simple moving average is $311.10 and its 200 day simple moving average is $271.50. The stock has a market cap of $21.66 billion, a P/E ratio of 47.43, a P/E/G ratio of 5.27 and a beta of 1.66.

Align Technology (NASDAQ:ALGN - Get Free Report) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.13. Align Technology had a return on equity of 14.15% and a net margin of 11.80%. The firm had revenue of $956.73 million for the quarter, compared to the consensus estimate of $928.57 million. Analysts predict that Align Technology, Inc. will post 7.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Morgan Stanley upped their price objective on Align Technology from $344.00 to $360.00 and gave the stock an "overweight" rating in a research note on Thursday, April 25th. SVB Leerink assumed coverage on shares of Align Technology in a report on Monday, February 26th. They issued a "market perform" rating and a $310.00 price target on the stock. UBS Group lifted their price objective on shares of Align Technology from $280.00 to $320.00 and gave the stock a "neutral" rating in a research report on Monday, April 15th. Stifel Nicolaus increased their target price on shares of Align Technology from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, April 18th. Finally, The Goldman Sachs Group raised their target price on shares of Align Technology from $197.00 to $225.00 and gave the company a "sell" rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $353.00.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.